Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1

Read also

Adjunctive Use Approved CBD

Study: Adjunctive Use of FDA-Approved CBD Formulation Reduces Seizures in Pediatric Patients With Rett Syndrome

Sanofi’s Tzield

Sanofi’s Tzield gains approval in China for T1D management

Capricor

Capricor refutes FDA’s DMD deramiocel rejection in public statement

Medison and Ipsen’s Bylvay

Health Canada approves Medison and Ipsen’s Bylvay to treat ALGS